CKD Stage Classification for GFR 46 mL/min/1.73 m²
A GFR of 46 mL/min/1.73 m² corresponds to Stage G3a chronic kidney disease, defined as mildly to moderately decreased kidney function (eGFR 45-59 mL/min/1.73 m²) according to the KDIGO classification system. 1
KDIGO Staging Framework
The KDIGO classification stratifies chronic kidney disease by eGFR as follows: 1
- Stage G1: ≥90 mL/min/1.73 m²
- Stage G2: 60-89 mL/min/1.73 m²
- Stage G3a: 45-59 mL/min/1.73 m² ← Your patient is here
- Stage G3b: 30-44 mL/min/1.73 m²
- Stage G4: 15-29 mL/min/1.73 m²
- Stage G5: <15 mL/min/1.73 m² (kidney failure)
Clinical Significance of Stage G3a
- Stage G3a represents loss of approximately one-third to one-half of normal kidney function and carries substantially increased risks compared to earlier stages. 1
- This stage is associated with elevated cardiovascular disease risk, accelerated CKD progression potential, and increased mortality compared to stages G1-G2. 1
Diagnostic Confirmation Requirements
- Chronic kidney disease diagnosis requires persistent abnormalities for at least three months; a single eGFR measurement of 46 mL/min/1.73 m² is insufficient to diagnose CKD. 1
- Repeat the eGFR measurement within 3 months to verify chronicity and rule out acute kidney injury. 1
- Do not rely on serum creatinine concentration alone to assess kidney function; eGFR must be calculated using validated equations. 1
Important Clinical Distinction
While your patient's GFR of 46 mL/min/1.73 m² places them in Stage G3a, it is critical to note that Stage G3b (30-44 mL/min/1.73 m²) carries significantly higher risks and warrants more aggressive monitoring and earlier nephrology involvement. 1 The subdivision of Stage 3 into 3a and 3b reflects meaningful differences in prognosis and management intensity.
Overlap with Normal Values
Healthy adults can have eGFR values as low as 63.5 mL/min/1.73 m² in some populations, meaning normal values overlap with CKD stages 1 and 2. 2 Therefore, an eGFR of 46 mL/min/1.73 m² definitively indicates reduced kidney function below the normal range and meets criteria for Stage G3a when persistent for ≥3 months.